Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28991077 | 0.90 | NPC1 (0.46) | LMNANPC1RAB9ACYP19A1POLB | |
| SCHEMBL23070396 | 0.90 | S1PR3 (0.37) | P2RX7LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL20477430 | 0.85 | CYP19A1 (0.52) | LMNANPC1RAB9ACYP19A1SMN1; SMN2 | |
| SCHEMBL25972169 | 0.85 | P2RY14 (0.34) | P2RX7NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL23070397 | 0.84 | LMNA (0.41) | P2RX7LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL24709700 | 0.84 | NPC1 (0.35) | P2RX7LMNANPC1RAB9ACYP19A1 | |
| SCHEMBL30122013 | 0.83 | NPC1 (0.40) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL23081454 | 0.83 | NPC1 (0.40) | LMNANPC1RAB9AKMT2AMEN1 | |
| SCHEMBL20477416 | 0.83 | ALDH1A1 (0.42) | LMNANPC1RAB9ACYP19A1SMN1; SMN2 | |
| SCHEMBL24709418 | 0.82 | P2RX7 (0.39) | P2RX7LMNANPC1RAB9ACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115867557-B | Azepine condensed ring compound and medical application thereof | 中国医药研究开发中心有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-117460731-A | Heterocyclic lactams, process for their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-08 | — | — | US | disclosed |
| CN-115867557-A | Azepine fused ring compounds and medical application thereof | 中国医药研究开发中心有限公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2022258052-A1 | HETEROCYCLIC LACTAM COMPOUND, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-12-15 | — | — | WO | disclosed |
| WO-2022237890-A1 | AZEPINE-TYPE FUSED RING COMPOUND AND PHARMACEUTICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-11-17 | — | — | WO | disclosed |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2021-04-01 | — | — | US | disclosed |
| WO-2021046515-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718612-B2 | Inhibitors of receptor interacting protein kinase I for the treatment of disease | RIPK1, RIPK2, RIPK4 | P2RX7 2216/4885LMNA 3119/4885NPC1 1506/4885 |
| US-20210094951-A1 | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASE | RIPK1, RIPK2, RIPK4 | P2RX7 2216/4885LMNA 3119/4885NPC1 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.